Gregory Sawicki

Gregory S. Sawicki, MD, MPH, is a pediatric pulmonologist and health services researcher with particular interest in addressing health outcomes, disease self-management, and adherence for children, adolescents, and young adults with chronic respiratory diseases including cystic fibrosis (CF) and asthma.

Dr. Sawicki’s primary research activities are currently focused on the process and outcomes of transition from pediatric to adult focused health care for adolescents with chronic medical conditions. He is conducting a NIH-funded mixed methods qualitative and survey study of adolescents and young adults with CF with the aim of exploring their current experiences with health care transition and disease self-management. In his recent work, he has helped to develop and validate a survey instrument to assess transition readiness for youth with chronic disease, the Transition Readiness Assessment Questionnaire (TRAQ). This instrument is currently being used in multiple health care transition studies throughout the country. He also is working on the development of quality measures to evaluate the transition to adult care for youth with chronic conditions.

BACKGROUND

Dr. Sawicki received his MD from Harvard Medical School in 2001. He completed residency in Boston Combined Residency Program in Pediatrics in 2004, followed by fellowship in Pediatric Pulmonology at Boston Children’s Hospital (2004-2007). He also completed the Harvard Pediatric Health Services Research Fellowship in 2007, receiving an MPH in Clinical Effectiveness at the Harvard School of Public Health. Dr. Sawicki is currently the Associate Director of the Cystic Fibrosis Center at Boston Children’s Hospital.

Specialties

• Asthma in Children
• Cough
• Cystic Fibrosis
• Pneumonia
• Respiratory Distress
• Tuberculosis TB

Departments

• Department of Pediatrics
• Division of Pulmonary Medicine

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

• Trajectories of the Transition Readiness Assessment Questionnaire Among Youth With Inflammatory Bowel Disease. J Clin Gastroenterol. 2021 Dec 15.
• Evaluating barriers to and promoters of telehealth during the COVID-19 pandemic at U.S. cystic fibrosis programs. J Cyst Fibros. 2021 12; 20 Suppl 3:9-13.
• Financial impacts of the COVID-19 pandemic on cystic fibrosis care: lessons for the future. J Cyst Fibros. 2021 12; 20 Suppl 3:16-20.
• Patient and family experience of telehealth care delivery as part of the CF chronic care model early in the COVID-19 pandemic. J Cyst Fibros. 2021 12; 20 Suppl 3:41-46.
• Remote monitoring in telehealth care delivery across the U.S. cystic fibrosis care network. J Cyst Fibros. 2021 12; 20 Suppl 3:57-63.
• Continuous Glucose Monitoring and HbA1c in Cystic Fibrosis: Clinical Correlations and Implications for CFRD Diagnosis. J Clin Endocrinol Metab. 2021 Nov 29.
• Prevalence, variability, and predictors of sinus surgery in pediatric patients with cystic fibrosis. Pediatr Pulmonol. 2021 12; 56(12):4029-4038.
• Onset timing of treadmill belt perturbations influences stability during walking. J Biomech. 2022 Jan; 130:110800.
• The effect of elexacaftor/tezacaftor/ivacaftor (ETI) on glycemia in adults with cystic fibrosis. J Cyst Fibros. 2021 Sep 13.
• Favorable Clinician Acceptability of Telehealth as Part of the Cystic Fibrosis Care Model during the COVID-19 Pandemic. Ann Am Thorac Soc. 2021 09; 18(9):1588-1592.
• Understanding the Intersection between Gender Transition and Health Outcomes in Cystic Fibrosis. Ann Am Thorac Soc. 2021 Sep 01.
• Perceptions of Social Media Use to Augment Health Care Among Adolescents and Young Adults With Cystic Fibrosis: Survey Study. JMIR Pediatr Parent. 2021 Aug 16; 4(3):e25014.
• Evaluating the Impact of Stopping Chronic Therapies after Modulator Drug Therapy in Cystic Fibrosis: The SIMPLIFY Clinical Trial Study Design. Ann Am Thorac Soc. 2021 08; 18(8):1397-1405.
• Disease burden in people with cystic fibrosis heterozygous for F508del and a minimal function mutation. J Cyst Fibros. 2021 Jul 19.
• The Effects of Ivacaftor on Bone Density and Microarchitecture in Children and Adults with Cystic Fibrosis. J Clin Endocrinol Metab. 2021 03 08; 106(3):e1248-e1261.
• Ivacaftor in Infants Aged 4 to <12 Months with Cystic Fibrosis and a Gating Mutation. Results of a Two-Part Phase 3 Clinical Trial. Am J Respir Crit Care Med. 2021 03 01; 203(5):585-593.
• Rapid Implementation of Telehealth Services in a Pediatric Pulmonary Clinic During COVID-19. Pediatrics. 2021 07; 148(1).
• An evaluation of healthcare utilization and clinical charges in children and adults with cystic fibrosis. Pediatr Pulmonol. 2021 05; 56(5):928-938.
• Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study. Lancet Respir Med. 2021 07; 9(7):733-746.
• Improvement of Pulmonary Function in Cystic Fibrosis Patients following Endoscopic Sinus Surgery. Laryngoscope. 2021 09; 131(9):1930-1938.
• Tribulations and (clinical) trials in cystic fibrosis. J Cyst Fibros. 2021 03; 20(2):188-190.
• Transition Readiness Not Associated With Measures of Health in Youth With IBD. Inflamm Bowel Dis. 2021 01 01; 27(1):49-57.
• Men's health in the modern era of cystic fibrosis. J Cyst Fibros. 2021 11; 20(6):e121-e123.
• Monogenic Diabetes in a Child with Cystic Fibrosis: A Case Report and Review of the Literature. J Endocr Soc. 2021 Jan 01; 5(1):bvaa165.
• Decreased survival in cystic fibrosis patients with a positive screen for depression. J Cyst Fibros. 2021 01; 20(1):120-126.
• Survey of patients with cystic fibrosis and caregivers decisions regarding CFTR modulators. Pediatr Pulmonol. 2020 11; 55(11):2983-2989.
• Caregiver Burden Due to Pulmonary Exacerbations in Patients with Cystic Fibrosis. J Pediatr. 2019 12; 215:164-171.e2.
• Male gender and unemployment are associated with lower levels of perceived social support in adults with cystic fibrosis. J Psychosom Res. 2019 12; 127:109858.
• Medical Deferred Action - Living on Borrowed Time. N Engl J Med. 2019 Oct 24; 381(17):1601-1603.
• Predictors of pulmonary exacerbation treatment in cystic fibrosis. J Cyst Fibros. 2020 05; 19(3):407-414.
• A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11?years with cystic fibrosis. J Cyst Fibros. 2019 09; 18(5):708-713.
• Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries. J Cyst Fibros. 2020 01; 19(1):68-79.
• Chronic rhino-sinusitis treatment in children with cystic fibrosis: A cross-sectional survey of pediatric pulmonologists and otolaryngologists. Int J Pediatr Otorhinolaryngol. 2019 Sep; 124:139-142.
• An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5?years (KLIMB). J Cyst Fibros. 2019 11; 18(6):838-843.
• Developing Sexual and Reproductive Health Educational Resources for Young Women with Cystic Fibrosis: A Structured Approach to Stakeholder Engagement. Patient. 2019 04; 12(2):267-276.
• Linkage of the CF foundation patient registry with the pediatric health information system database. Pediatr Pulmonol. 2019 06; 54(6):721-728.
• Interprofessional provider educational needs and preferences regarding the provision of sexual and reproductive health care in cystic fibrosis. J Cyst Fibros. 2019 09; 18(5):671-676.
• Social support is associated with fewer reported symptoms and decreased treatment burden in adults with cystic fibrosis. J Cyst Fibros. 2019 07; 18(4):572-576.
• Cystic Fibrosis And Ivacaftor Use: The Authors Reply. Health Aff (Millwood). 2019 02; 38(2):328.
• Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study. Lancet Respir Med. 2019 04; 7(4):325-335.
• Healthcare expenditures for privately insured US patients with cystic fibrosis, 2010-2016. Pediatr Pulmonol. 2018 12; 53(12):1611-1618.
• Disparities in Mortality of Hispanic Patients with Cystic Fibrosis in the United States. A National and Regional Cohort Study. Am J Respir Crit Care Med. 2018 10 15; 198(8):1055-1063.
• Transition to adulthood and adult health care for patients with sickle cell disease or cystic fibrosis: Current practices and research priorities. J Clin Transl Sci. 2018 Oct; 2(5):334-342.
• Rate and predictors of prescription of lumacaftor - Ivacaftor in the 18?months following approval in the United States. J Cyst Fibros. 2018 11; 17(6):742-746.
• Sexual and Reproductive Health of Young Women With Cystic Fibrosis: A Concept Mapping Study. Acad Pediatr. 2019 04; 19(3):307-314.
• The burden of cystic fibrosis in the Medicaid population. Clinicoecon Outcomes Res. 2018; 10:423-431.
• Overcoming psychosocial challenges in cystic fibrosis: Promoting resilience. Pediatr Pulmonol. 2018 11; 53(S3):S86-S92.
• Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor. Thorax. 2018 08; 73(8):731-740.
• Precision Medicine In Action: The Impact Of Ivacaftor On Cystic Fibrosis-Related Hospitalizations. Health Aff (Millwood). 2018 05; 37(5):773-779.
• Perspectives of adolescent girls with cystic fibrosis and parents on disease-specific sexual and reproductive health education. Pediatr Pulmonol. 2018 08; 53(8):1027-1034.